Everolimus improves progression-free survival for patients with rare pancreatic cancer, study finds
Wednesday, February 9, 2011 - 18:30
in Health & Medicine
In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), has shown to dramatically improve progression-free survival for patients with advanced pancreatic neuroendocrine tumors (pNET), according to researchers.
